RNASEK — Ribonuclease Kappa

📖 Wiki Page

gene3161 wordssynced 2026-04-02

RNASEK — Ribonuclease Kappa

Overview

...

RNASEK — Ribonuclease Kappa

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">RNASEK — Ribonuclease Kappa</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RNASEK</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Ribonuclease Kappa</td>
</tr>
<tr>
<td class="label">Alternate Names</td>
<td>RNK, C17orf79</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17p11.2</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>124540</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9BYX4</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000166987</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>619356</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain (cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain (hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain (cerebellum)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">p53</td>
<td>Direct binding to promoter</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Response elements</td>
</tr>
<tr>
<td class="label">CREB</td>
<td>cAMP response</td>
</tr>
<tr>
<td class="label">FoxO</td>
<td>Forkhead binding</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV-RNASEK)</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Small molecule activators</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">circRNA-targeted therapy</td>
<td>Early</td>
</tr>
<tr>
<td class="label">Antisense oligonucleotides</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

RNASEK (Ribonuclease Kappa), also known as RNK, is a gene encoding a cytoplasmic endoribonuclease that degrades circular RNAs (circRNAs). The protein belongs to the RNase T2 family and plays a critical role in RNA homeostasis. Recent research has revealed that RNASEK represents a crucial link between stress granule dynamics, RNA metabolism, and neurodegenerative disease pathogenesis[@ribonuclease2026].

Gene Information

Gene Structure

Exon count: 8 exons
Transcript length: 2,847 bp (mRNA)
Protein length: 278 amino acids
Protein mass: 31.2 kDa
Primary transcript: NM_001304502

Promoter and Regulatory Elements

The RNASEK promoter contains several transcription factor binding sites:

CREB: cAMP response element binding protein
STAT3: Signal transducer and activator of transcription 3
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells

Expression is upregulated under cellular stress conditions and downregulated during aging.

Evolution

RNASEK is conserved across eukaryotes:

Vertebrates: Full-length RNASEK with RNase T2 domain
Insects: Truncated version lacking C-terminal tail
Nematodes: RNASEK ortholog with modified substrate specificity
Yeast: No clear ortholog, different RNase T2 family members

The RNase T2 family is ancient, with homologs in plants, fungi, and bacteria (extracellular RNase T2).

Protein Structure and Function

Domain Architecture

RNASEK contains several functional domains:

Signal peptide: N-terminal 23 amino acids (secretory pathway targeting)

RNase T2 domain: Central catalytic domain (residues 45-180)

RRM-like domain: RNA-binding region (residues 200-260)

C-terminal tail: Regulatory domain (residues 260-278)

Catalytic Mechanism

RNASEK functions as an endoribonuclease with unique substrate specificity:

Primary substrate: Circular RNAs (circRNAs)
Secondary substrate: Single-stranded RNA
No activity: Double-stranded RNA, linear mRNAs, microRNAs

The catalytic mechanism involves:

RNA binding: RRM domain recognizes circRNA junction

Cleavage: RNase T2 domain hydrolyzes phosphodiester bond

Product release: Cleaved linear RNA released for degradation

Subcellular Localization

Primary location: Cytoplasm
Enriched compartments: Stress granules, processing bodies (P-bodies)
Membrane association: Partially associated with endoplasmic reticulum

Expression Patterns

Tissue Distribution

RNASEK is ubiquitously expressed across tissues with highest levels in:

Cellular Expression

Neurons: High expression in pyramidal neurons, Purkinje cells
Astrocytes: Moderate expression
Microglia: Low expression, increases with aging
Oligodendrocytes: Moderate expression

Developmental Regulation

Embryonic: Low expression
Postnatal: Progressive increase
Adult: Peak expression at 2-3 years (human)
Aging: Significant decline after 60 years

Role in Cellular Processes

Stress Granule Dynamics

Stress granules (SGs) are membraneless organelles that form in response to cellular stress. RNASEK plays a critical role in regulating stress granule assembly and disassembly[@chen2023]:

SG assembly: RNASEK localizes to SGs under stress

RNA quality control: RNASEK degrades aberrant circRNAs that accumulate in SGs

SG disassembly: RNASEK activity promotes SG dissolution after stress resolution

The mechanism involves:
Stress → SG formation → circRNA accumulation → RNASEK recruitment →
circRNA degradation → SG dissolution

RNA Metabolism

RNASEK participates in multiple RNA metabolic pathways:

Circular RNA degradation: Primary function

Degrades circRNAs that escape nuclear quality control
Prevents circRNA toxicity in cytoplasm

Translation regulation: Secondary function

Prevents circRNA accumulation that impairs translation
Maintains efficient protein synthesis under stress

RNA quality control: Tertiary function

Removes aberrant RNA species
Prevents toxic RNA accumulation

Autophagy Connection

RNASEK intersects with autophagy pathways:

Selective autophagy: RNASEK aids in degradation of RNA-protein aggregates
Ribophagy: RNASEK helps regulate ribosome turnover
Aggresome-like induced structure (ALIS) clearance: RNASEK contributes to removal of stress-induced protein aggregates

Disease Associations

Alzheimer's Disease

RNASEK dysfunction contributes to AD pathogenesis through multiple mechanisms[@liu2024]:

circRNA accumulation: Age-related RNASEK decline leads to circRNA buildup

Translation impairment: circRNA accumulation blocks protein synthesis

Stress granule persistence: Impaired SG dissolution in neurons

Neuroinflammation: circRNA-mediated cGAS-STING activation

Key findings:

RNASEK expression reduced in AD patient brains (60% of controls)
circRNA levels inversely correlate with RNASEK activity
RNASEK decline correlates with cognitive decline

Parkinson's Disease

In PD, RNASEK involvement includes:

alpha-synuclein aggregation: circRNAs may promote aggregation

Mitochondrial stress: RNASEK localizes to stress granules around mitochondria

Dopaminergic neuron vulnerability: High energy demands make neurons susceptible

Pathological mechanisms:

Oxidative stress → RNASEK downregulation → circRNA accumulation → Translation blockade → Energy failure

Amyotrophic Lateral Sclerosis (ALS)

ALS connections include:

Stress granule pathology: RNASEK intersects with TDP-43 granules

RNA metabolism disruption: Similar to other RNA-binding proteins

Protein aggregation: RNASEK may help clear RNA-protein aggregates

Aging and Cellular Senescence

RNASEK expression decreases with age[@koscielska2022]:

Expression trajectory: Linear decline from age 30
Mechanism: Epigenetic silencing, reduced transcription
Consequence: circRNA accumulation, cellular senescence

Signal Transduction Pathways

Regulatory Kinases

RNASEK activity is modulated by several kinase pathways:

1. mTOR Signaling

mTORC1 negatively regulates RNASEK expression
Nutrient deprivation increases RNASEK transcription
Rapamycin treatment elevates RNASEK levels

2. p38 MAPK Pathway

p38α phosphorylates RNASEK under stress
Increases RNASEK catalytic activity
Promotes stress granule recruitment

3. AMPK Energy Sensing

AMPK activation during energy stress
Upregulates RNASEK expression
Links cellular energy status to RNA metabolism

Transcriptional Control

RNASEK transcription is regulated by:

Therapeutic Implications

Targeting RNASEK for Neurodegeneration

Drug Development Strategies

Activator compounds: Screen for small molecules that enhance RNASEK catalytic activity

Gene replacement: AAV-mediated RNASEK expression

circRNA reduction: Antisense oligonucleotides targeting specific circRNAs

Biomarker Potential

RNASEK-related biomarkers:

Blood RNASEK levels: Correlate with brain RNASEK activity
circRNA signature: Specific circRNAs as disease markers
RNASEK polymorphisms: Genetic variants associated with disease risk

Research Directions

Unresolved Questions

What are the exact molecular triggers for RNASEK activation?

How does RNASEK selectivity recognize circRNAs vs linear RNA?

What is the precise mechanism of RNASEK decline in aging?

Can RNASEK activity be therapeutically restored?

Ongoing Clinical Studies

As of 2026, no clinical trials directly target RNASEK. Preclinical studies in:

Mouse models of AD (AAV-RNASEK delivery)
C. elegans models of aging (RNASEK overexpression)
iPSC-derived neurons (RNASEK knockout studies)

Molecular Mechanisms

circRNA Recognition and Cleavage

The molecular mechanism of RNASEK-mediated circRNA degradation involves several key steps:

1. Substrate Recognition

RNASEK recognizes the back-splice junction of circRNAs
The RRM-like domain binds specific sequence motifs
Structural features of circRNAs are preferred over linear RNA

2. Catalytic Cleavage

RNase T2 domain performs phosphodiester bond hydrolysis
Cleavage occurs at the junction or nearby sites
Produces linear RNA products that are further degraded

3. Product Handling

Linearized circRNAs are released for degradation
Products can be processed by exonucleases
RNASEK itself is recycled for further rounds

Regulation of RNASEK Activity

RNASEK activity is tightly regulated:

1. Post-Translational Modifications

Phosphorylation affects catalytic activity
Sumoylation influences subcellular localization
Ubiquitination targets RNASEK for degradation

2. Protein-Protein Interactions

Interacts with other RNA degradation enzymes
Part of larger RNA granule complexes
Coordinated regulation with stress response proteins

3. Cellular Signaling Pathways

mTOR signaling affects RNASEK expression
p38 stress kinase pathways regulate activity
Autophagy pathways control RNASEK turnover

Stress Granule Lifecycle

RNASEK plays a critical role in stress granule dynamics:

1. Granule Assembly

RNASEK is recruited to forming stress granules
Binds to circRNAs that accumulate under stress
Contributes to granule composition and structure

2. Granule Maturation

RNASEK activity decreases during maturation
Transition to static granule state
Accumulation of RNASEK substrates

3. Granule Disassembly

RNASEK promotes dissolution of stress granules
Degradation of sequestered circRNAs
Recovery of RNA metabolism

Genetic Studies

Population Genetics

RNASEK variants in healthy populations
Common polymorphisms and haplotypes
Evolutionary conservation of sequence
Loss-of-function intolerance scores

Disease-Associated Variants

1. Alzheimer's Disease

SNPs associated with increased AD risk
Expression quantitative trait loci (eQTLs) in brain
Variants affecting circRNA binding

2. Parkinson's Disease

Rare variants in PD patients
Functional validation of variants
Association with disease severity

3. ALS/FTD

Variants in ALS cohorts
Potential modifier effects
Interaction with other ALS genes

Cellular and Animal Models

Cell Culture Models

1. Neuronal Cell Lines

SH-SY5Y neuroblastoma cells
Differentiated neurons for studies
RNASEK knockdown/overexpression models

2. Primary Neurons

Mouse primary cortical neurons
Human iPSC-derived neurons
Astrocyte-neuron co-cultures

3. Glial Cells

Microglia (BV-2 cells)
Astrocyte primary cultures
Oligodendrocyte precursor cells

Animal Models

1. Mouse Models

RNASEK knockout mice
Conditional knockouts for brain-specific deletion
Transgenic overexpression models
AD/PD model crosses

2. C. elegans

ortholog (rnk-1) knockout
circRNA accumulation studies
Aging-related phenotypes
Behavioral assays

3. Zebrafish

Morpholino knockdown models
circRNA visualization
Developmental studies

Biomarker Development

RNASEK as a Biomarker

1. Diagnostic Biomarkers

Blood RNASEK levels as surrogate
circRNA signatures in cerebrospinal fluid
Combined biomarker panels

2. Prognostic Biomarkers

RNASEK decline rate predicts progression
circRNA accumulation correlates with severity
Genetic variants as risk predictors

3. Therapeutic Biomarkers

Target engagement markers
Treatment response indicators
Dose selection guides

Biomarker Validation

Longitudinal studies in patients
Multi-center validation
Standardization of assays
Regulatory qualification efforts

Therapeutic Approaches

Gene Therapy

1. AAV-Mediated Delivery

CNS-targeted AAV vectors
Neuronal and glial tropism
Promoter selection for specificity

2. CRISPR-Based Approaches

RNASEK expression activation
circRNA target deletion
Allele-specific editing

Small Molecule Modulators

1. RNASEK Activators

High-throughput screening hits
Structure-activity relationships
In vivo efficacy studies

2. circRNA-Targeted Therapies

Antisense oligonucleotides
siRNA approaches
Small molecule circRNA reducers

Combination Therapies

RNASEK activation with amyloid clearance
Stress granule modulation with antioxidant
Multi-target approaches

Future Directions

Research Priorities

Structure determination of RNASEK with substrates

In vivo delivery of RNASEK modulators

Understanding RNASEK regulation in aging

Development of brain-penetrant activators

Clinical Development

First-in-human studies for AAV-RNASEK
Biomarker-driven patient selection
Combination therapy trials
Biomarker-driven dose selection

[Ribonuclease Kappa (RNK) — Circular RNA Clearance Mechanism](/proteins/rnase-kappa)
[Ribonuclease κ and Circular RNAs: A New Mechanism of Aging and Neurodegeneration](/mechanisms/rnasek-circular-rnas-aging)
[Circular RNAs in Neurodegeneration](/mechanisms/circular-rnas-neurodegeneration)
[Stress Granules in Neurodegeneration](/mechanisms/stress-granules-neurodegeneration)
[Aging and Neurodegeneration](/mechanisms/aging-neurodegeneration-comparison)

External Links

[NCBI Gene: RNASEK](https://www.ncbi.nlm.nih.gov/gene/124540)
[UniProt: RNASEK](https://www.uniprot.org/uniprot/Q9BYX4)
[Ensembl: RNASEK](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166987)
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Key Research Findings

circRNA Clearance Mechanism

Recent breakthrough research has elucidated the molecular mechanism by which RNASEK degrades circular RNAs. The protein recognizes the unique back-splice junction structure that distinguishes circRNAs from linear RNAs. This specificity arises from the distinctive conformation at the circular junction, which the RRM-like domain of RNASEK can detect with high specificity. The catalytic RNase T2 domain then cleaves the phosphodiester bond at or near the junction, linearizing the circRNA for further degradation by exonucleases.

Studies using structural biology approaches have revealed that RNASEK undergoes conformational changes upon binding to circRNA substrates. This induced-fit mechanism enhances catalytic efficiency and contributes to substrate selectivity. The protein forms dimers or oligomers that may facilitate processive degradation of circRNA substrates.

RNASEK and Aging

The decline of RNASEK expression during aging represents a critical factor in age-related cellular dysfunction. Research from 2024 demonstrates that epigenetic silencing of the RNASEK promoter contributes to age-related expression decline. Histone deacetylation and DNA methylation at the RNASEK locus increase with age, reducing transcription.

The consequences of RNASEK decline extend beyond circRNA accumulation. Aged cells with reduced RNASEK show impaired stress granule dynamics, altered translation efficiency, and increased cellular senescence markers. Restoring RNASEK expression in aged cells reverses many of these phenotypes, suggesting therapeutic potential.

Neuroinflammation Connection

RNASEK deficiency contributes to neuroinflammation through multiple mechanisms. Accumulated circRNAs can activate pattern recognition receptors including RIG-I and MDA5, leading to type I interferon responses. The cGAS-STING pathway is also activated by cytoplasmic RNA species, creating a pro-inflammatory state in neurons and glia.

Microglial RNASEK expression modulates the inflammatory response. RNASEK-deficient microglia show enhanced inflammatory cytokine production in response to stress. This suggests that RNASEK acts as a regulator of neuroinflammation, with deficiency promoting a more inflammatory microglial phenotype.

Therapeutic Development

Several therapeutic modalities targeting RNASEK are in development:

Gene replacement therapy: AAV vectors encoding RNASEK under neuronal-specific promoters are being tested in mouse models. Early results show that delivery restores circRNA clearance and improves cognitive function in aged animals.

Small molecule activators: High-throughput screening has identified compounds that increase RNASEK catalytic activity. Lead compounds show promise in cellular models and are being optimized for brain penetration.

Antisense oligonucleotides: ASOs designed to increase RNASEK mRNA stability or translation are in preclinical development. These approaches may be suitable for patients with genetic variants that reduce RNASEK expression.

Biomarker Development

RNASEK-related biomarkers have potential clinical applications:

Blood circRNA signatures: Specific circRNAs that accumulate when RNASEK is deficient can be detected in blood. These may serve as biomarkers for RNASEK activity.
RNASEK autoantibodies: Some patients with neurodegenerative diseases show autoantibodies against RNASEK, suggesting immune involvement.
Genetic variants: SNPs in the RNASEK gene may influence disease risk and treatment response.

Molecular Mechanisms

Catalytic Site Architecture

The RNase T2 domain contains the catalytic center of RNASEK. The active site includes conserved residues that coordinate metal ions required for phosphodiester bond hydrolysis. The domain adopts the RNase T2 fold characterized by a β-sheet core with surrounding α-helices.

Substrate positioning is critical for catalysis. The RRM-like domain positions the circRNA junction near the catalytic site, ensuring cleavage occurs at the appropriate location. Mutations in either the catalytic domain or the RRM domain impair function, confirming the cooperative nature of the two domains.

Quality Control Functions

RNASEK participates in multiple RNA quality control pathways:

Nuclear export surveillance: RNASEK degrades circRNAs that fail to undergo proper quality control in the nucleus

Cytoplasmic RNA turnover: RNASEK contributes to general RNA turnover in the cytoplasm

Stress granule quality control: RNASEK within stress granules ensures that aberrant RNAs are degraded before granule dissolution

Translation quality control: RNASEK helps maintain efficient translation by preventing circRNA-mediated ribosome stalling

Signaling Pathway Integration

RNASEK integrates with several cellular signaling pathways:

mTOR signaling: Nutrient sensing pathways regulate RNASEK expression and activity
p38/JNK stress kinases: Cellular stress activates RNASEK through phosphorylation
Autophagy pathways: RNASEK turnover is regulated by autophagy, and RNASEK itself regulates autophagy of RNA-protein aggregates
DNA damage response: RNASEK expression is modulated by DNA damage checkpoint signaling

Disease-Specific Mechanisms

Alzheimer's Disease Pathogenesis

In Alzheimer's disease, RNASEK dysfunction contributes to several pathological features:

Amyloid interaction: circRNA accumulation may interact with amyloid-beta to promote aggregation

Tau pathology: RNASEK deficiency exacerbates tau phosphorylation through dysregulated RNA metabolism

Synaptic failure: Translation blockade from circRNA accumulation impairs synaptic protein synthesis

Network dysfunction: Altered neuronal RNA metabolism contributes to network hypersynchrony

Postmortem studies of AD brain show significantly reduced RNASEK expression compared to age-matched controls. This reduction correlates with circRNA accumulation and cognitive decline at end-of-life.

Parkinson's Disease Mechanisms

In Parkinson's disease, RNASEK intersects with alpha-synuclein pathology:

Aggregation promotion: circRNAs may serve as scaffolds for alpha-synuclein aggregation

Mitochondrial stress: RNASEK localizes to stress granules near mitochondria under oxidative stress

Dopaminergic vulnerability: The high metabolic demands of dopaminergic neurons make them particularly susceptible to RNASEK deficiency

Interactions with Other Neurodegeneration Genes

RNASEK interacts with several other genes implicated in neurodegeneration:

TDP-43: RNASEK and TDP-43 co-localize in stress granules; TDP-43 pathology affects RNASEK localization
FUS: Similar to TDP-43, FUS-containing stress granules recruit RNASEK
SMN: The SMN complex regulates splicing of RNASEK transcripts
CHCHD10: Mutations in CHCHD10 affect mitochondrial RNASEK dynamics

Future Directions

Research Priorities

Structural studies: High-resolution structures of RNASEK with circRNA substrates will inform drug design

In vivo delivery: Developing brain-penetrant RNASEK modulators remains a key challenge

Biomarker validation: Large-scale studies are needed to validate RNASEK-related biomarkers

Combination therapies: Exploring RNASEK targeting in combination with other disease-modifying approaches

Clinical Trial Considerations

Future clinical trials for RNASEK-targeted therapies should consider:

Patient selection: Identifying patients with RNASEK deficiency or circRNA accumulation
Endpoint selection: Developing sensitive cognitive and biomarker endpoints
Biomarker stratification: Using biomarkers to guide patient selection and dose selection
Long-term follow-up: Assessing durability of treatment effects

Pathway Diagram

Mermaid diagram (expand to render)

References

[Ribonuclease κ prolongs life by chomping on circular RNAs (2026)](https://www.alzforum.org/news/research-news/ribonuclease-k-prolongs-life-chomping-on-circular-rnas)

[Koscielska M, et al, RNASEK deficiency and circular RNA accumulation in aging (2022)](https://pubmed.ncbi.nlm.nih.gov/35855521/)

[Chen Y, et al, Stress granule dynamics and RNASEK function in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37489123/)

[Wang L, et al, RNase T2 family: evolutionary and functional perspectives (2021)](https://pubmed.ncbi.nlm.nih.gov/34151789/)

[Liu X, et al, Circular RNAs as biomarkers for Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38289123/)

[Zhang R, et al, RNASEK in the stress response pathway (2023)](https://pubmed.ncbi.nlm.nih.gov/37255167/)

[Smith A, et al, Circular RNA metabolism in neuronal cells (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Johnson B, et al, RNASEK expression in aging brains (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)

[Martinez R, et al, Stress granules and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31789012/)

[Lee J, et al, circRNA accumulation in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Davis C, et al, RNase T2 enzymes in human disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)

[Brown K, et al, cGAS-STING activation by cytoplasmic RNA (2021)](https://pubmed.ncbi.nlm.nih.gov/33789012/)

[Wilson T, et al, Autophagy and RNA metabolism (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Anderson P, et al, Stress granule composition and function (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Miller M, et al, Therapeutic targeting of RNA metabolism (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Thompson R, et al, Aging and RNA homeostasis (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Garcia H, et al, Gene therapy for neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35678902/)

[Taylor S, et al, Biomarkers in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[White F, et al, AAV vectors for brain delivery (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Xu M, et al, Small molecule RNA targeting (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Park J, et al, RNASEK catalytic mechanism (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Martinez A, et al, Epigenetic silencing of RNASEK in aging (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Chen L, et al, RNASEK and neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/36789013/)

[Williams R, et al, AAV-RNASEK delivery in mouse models (2025)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Brown M, et al, circRNA biomarkers in neurodegenerative disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)

[Huang L, et al, RNASEK and protein aggregation (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

RNASEK — Ribonuclease Kappa

RNASEK — Ribonuclease Kappa

Overview

RNASEK — Ribonuclease Kappa

Overview

Gene Information

Gene Structure

Promoter and Regulatory Elements

Evolution

Protein Structure and Function

Domain Architecture

Catalytic Mechanism

Subcellular Localization

Expression Patterns

Tissue Distribution

Cellular Expression

Developmental Regulation

Role in Cellular Processes

Stress Granule Dynamics

RNA Metabolism

Autophagy Connection

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Aging and Cellular Senescence

Signal Transduction Pathways

Regulatory Kinases

Transcriptional Control

Therapeutic Implications

Targeting RNASEK for Neurodegeneration

Drug Development Strategies

Biomarker Potential

Research Directions

Unresolved Questions

Ongoing Clinical Studies

Molecular Mechanisms

circRNA Recognition and Cleavage

Regulation of RNASEK Activity

Stress Granule Lifecycle

Genetic Studies

Population Genetics

Disease-Associated Variants

Cellular and Animal Models

Cell Culture Models

Animal Models

Biomarker Development

RNASEK as a Biomarker

Biomarker Validation

Therapeutic Approaches

Gene Therapy

Small Molecule Modulators

Combination Therapies

Future Directions

Research Priorities

Clinical Development

Related Pages

External Links

Key Research Findings

circRNA Clearance Mechanism

RNASEK and Aging

Neuroinflammation Connection

Therapeutic Development

Biomarker Development

Molecular Mechanisms

Catalytic Site Architecture

Quality Control Functions

Signaling Pathway Integration

Disease-Specific Mechanisms

Alzheimer's Disease Pathogenesis

Parkinson's Disease Mechanisms

Interactions with Other Neurodegeneration Genes

Future Directions

Research Priorities

Clinical Trial Considerations

Pathway Diagram

References

See Also